$167 Million is the total value of Birchview Capital, LP's 62 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BDSX | BIODESIX INC | $14,596,000 | -35.0% | 1,104,953 | 0.0% | 8.73% | -34.5% | |
NBIX | NEUROCRINE BIOSCIENCES INC | $7,805,000 | +0.1% | 80,200 | 0.0% | 4.67% | +0.8% | |
BIIB | BIOGEN INC | $4,190,000 | +23.8% | 12,100 | 0.0% | 2.51% | +24.7% | |
ALBO | ALBIREO PHARMA INC | $3,905,000 | -0.2% | 111,000 | 0.0% | 2.34% | +0.6% | |
FHTX | FOGHORN THERAPEUTICS INC | $3,352,000 | -19.0% | 314,143 | 0.0% | 2.00% | -18.4% | |
UTHR | UNITED THERAPEUTICS CORP | $3,229,000 | +7.2% | 18,000 | 0.0% | 1.93% | +8.0% | |
KPTI | KARYOPHARM THERAPEUTICS INC | $2,374,000 | -1.9% | 230,000 | 0.0% | 1.42% | -1.2% | |
XLRN | ACCELERON PHARMA INC | $2,343,000 | -7.5% | 18,672 | 0.0% | 1.40% | -6.7% | |
MASI | MASIMO CORP | $1,940,000 | +5.6% | 8,000 | 0.0% | 1.16% | +6.3% | |
ANGN | ANGION BIOMEDICA CORP | $1,938,000 | +77.0% | 60,615 | 0.0% | 1.16% | +78.3% | |
VNDA | VANDA PHARMACEUTICALS INC | $1,721,000 | +43.2% | 80,000 | 0.0% | 1.03% | +44.1% | |
HROW | HARROW HEALTH INC | $1,672,000 | +37.6% | 180,000 | 0.0% | 1.00% | +38.7% | |
ARNA | ARENA PHARMACEUTICALS INC | $1,500,000 | -1.8% | 22,000 | 0.0% | 0.90% | -1.1% | |
CLR | CONTINENTAL RESOURCES INC | $1,468,000 | +46.9% | 38,600 | 0.0% | 0.88% | +48.1% | |
AMRN | AMARIN CORP PLCspons adr new | $1,314,000 | -29.5% | 300,000 | 0.0% | 0.79% | -28.9% | |
IMGN | IMMUNOGEN INC | $1,252,000 | -18.6% | 190,000 | 0.0% | 0.75% | -18.1% | |
ARVN | ARVINAS INC | $1,155,000 | +16.4% | 15,000 | 0.0% | 0.69% | +17.3% | |
ETRN | EQUITRANS MIDSTREAM CORPORATIO | $1,132,000 | +4.2% | 133,050 | 0.0% | 0.68% | +5.0% | |
CORT | CORCEPT THERAPEUTICS INC | $1,100,000 | -7.6% | 50,000 | 0.0% | 0.66% | -6.8% | |
SLNO | SOLENO THERAPEUTICS INC | $1,000,000 | -9.5% | 876,899 | 0.0% | 0.60% | -8.8% | |
BHVN | BIOHAVEN PHARMACEUTICAL HOLDING CO LTD | $971,000 | +42.0% | 10,000 | 0.0% | 0.58% | +43.1% | |
PROG | PROGENITY INC | $964,000 | -25.0% | 270,000 | 0.0% | 0.58% | -24.4% | |
KALV | KALVISTA PHARMACEUTICALS INC | $958,000 | -6.8% | 40,000 | 0.0% | 0.57% | -6.1% | |
PGNY | PROGYNY INC | $885,000 | +32.5% | 15,000 | 0.0% | 0.53% | +33.2% | |
CFRX | CONTRAFECT CORP | $880,000 | -8.3% | 200,000 | 0.0% | 0.53% | -7.7% | |
GTHX | G1 THERAPEUTICS INC | $878,000 | -8.7% | 40,000 | 0.0% | 0.52% | -8.1% | |
TBIO | TRANSLATE BIO INC | $826,000 | +66.9% | 30,000 | 0.0% | 0.49% | +68.0% | |
NARI | INARI MEDICAL INC | $653,000 | -12.8% | 7,000 | 0.0% | 0.39% | -12.1% | |
PXD | PIONEER NATURAL RESOURCES CO | $618,000 | +2.3% | 3,800 | 0.0% | 0.37% | +3.1% | |
TGTX | TG THERAPEUTICS INC | $582,000 | -19.5% | 15,000 | 0.0% | 0.35% | -18.9% | |
AWH | ASPIRA WOMENS HEALTH INC | $579,000 | -16.8% | 103,104 | 0.0% | 0.35% | -16.2% | |
APLS | APELLIS PHARMACEUTICALS INC | $506,000 | +47.5% | 8,000 | 0.0% | 0.30% | +48.5% | |
STOK | STOKE THERAPEUTICS INC | $505,000 | -13.4% | 15,000 | 0.0% | 0.30% | -12.7% | |
PTGX | PROTAGONIST THERAPEUTICS INC | $449,000 | +73.4% | 10,000 | 0.0% | 0.27% | +74.7% | |
XNCR | XENCOR INC | $424,000 | -20.0% | 12,300 | 0.0% | 0.25% | -19.4% | |
LSF | LAIRD SUPERFOOD INC | $418,000 | -20.4% | 14,000 | 0.0% | 0.25% | -19.9% | |
CCXI | CHEMOCENTRYX INC | $402,000 | -73.8% | 30,000 | 0.0% | 0.24% | -73.7% | |
DRNA | DICERNA PHARMACEUTICALS INC | $373,000 | +45.7% | 10,000 | 0.0% | 0.22% | +46.7% | |
FOLD | AMICUS THERAPEUTICS INC | $366,000 | -2.4% | 38,000 | 0.0% | 0.22% | -1.8% | |
BCRX | BIOCRYST PHARMACEUTICALS INC | $316,000 | +55.7% | 20,000 | 0.0% | 0.19% | +56.2% | |
ARQT | ARCUTIS BIOTHERAPEUTICS INC | $246,000 | -5.4% | 9,000 | 0.0% | 0.15% | -4.5% | |
IFRX | INFLARX NV | $208,000 | -23.8% | 70,000 | 0.0% | 0.12% | -23.5% | |
TXMD | THERAPEUTICSMD INC | $119,000 | -11.2% | 100,000 | 0.0% | 0.07% | -11.2% | |
CNCE | CONCERT PHARMACEUTICALS INC | $84,000 | -16.0% | 20,000 | 0.0% | 0.05% | -15.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-10
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
MASIMO CORP | 36 | Q3 2023 | 2.2% |
PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
XENCOR INC | 35 | Q3 2023 | 0.4% |
NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
BIOGEN INC | 31 | Q2 2022 | 3.1% |
CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
3/A | 2024-02-20 |
4/A | 2024-02-20 |
SC 13G/A | 2024-02-20 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-08 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-04-07 |
4 | 2023-03-27 |
3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.